Female sexual dysfunction: What's new?

Current Opinion in Obstetrics and Gynecology

Volumn 19, Issue 6, 2007, Pages 536-540

  Mayer, Margit E ^a   Bauer, Ricarda M ^a   Schorsch, Isabell ^a   Sonnenberg, Joachim E ^b   Stief, Christian G ^a   Ückert, Stefan ^b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Sexual Function Research Unit   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Classification; Diagnosis; Female sexual dysfunction; Nonpharmacological and pharmacological treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTILIPEMIC AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREMELANOTIDE; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN DERIVATIVE; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; ORAL CONTRACEPTIVE AGENT; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TESTOSTERONE; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; ORGASM DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SEXUAL AROUSAL DISORDER;

ADRENERGIC ALPHA-ANTAGONISTS; DIAGNOSIS, DIFFERENTIAL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PHOSPHODIESTERASE INHIBITORS; PSYCHOTHERAPY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 36249005381     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f1c733     Document Type: Review

References (41)

1. Geiss I. Weibliche Sexualstörungen [Female sexual dysfunction]. J Fertil Reprod 2006; 16:6-12. This is a condensed review on important aspects of FSD.
2. Basson R, Althof S, Davis S, et al. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2004; 1:24-34.
3. Basson R. Female sexual response: a different model. J Sex Marital Ther 2003; 26:51-65.
4. Basson R, Bermann J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definition and classifications. J Urol 2000; 163:888-893.
5. Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28:317-330.
6. Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1:49-57.
7. Pauls RN, Kleeman SD, Karram MM. Female sexual dysfunction: principles of diagnosis and therapy. Obstet Gynecol Surv 2005; 60:196-205.
8. Mandal S, Goldstein I, Berman JR. Clinical evaluation of female sexual dysfunction: new diagnostic and treatment strategies. Prim Psychiatry 2001; 8:54-59.
9. Kaya C, Yilmaz G, Nurkalem Z, et al. Sexual function in women with coronary artery disease: a preliminary study. Int J Impot Res 2007; 19:326-329.
10. Ottem DP, Carr LK, Perks AE, et al. Interstitial cystitis and female sexual dysfunction. Urology 2007; 69:608-610.
11. Aslan G, Koseoglu H, Sadik O, et al. Sexual function in women with urinary incontinence. Int J Impot Res 2005; 17:248-251.
12. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004; 1:82-86.
13. Guay A, Jacobson J, Munarriz R, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels in healthy premenopausal women with complaints of sexual dysfunction. Int J Impot Res 2004; 16:121-129.
14. Berman JR, Mccarthy MM, Kyprianou N. Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology 1998; 51:650-656.
15. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behaviour in postmenopause. J Womens Health Gend Based Med 2000; 9 (Suppl 1):25-32.
16. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90:5226-5233.
17. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999; 56:201-208.
18. Thomas DR. Medications and sexual function. Clin Geriatr Med 2003; 19:553-562.
19. Halvorsen JG, Metz ME. Sexual dysfunction, Part II: Diagnosis, management, and prognosis. J Am Board Fam Pract 1992; 5:177-192.
20. Bartlik B, Kocsis JH, Legere R, et al. Sexual dysfunction secondary to depressive disorders. J Gend Specif Med 1999; 2:52-60.
21. Trudel G, Marchand A, Ravart M, et al. The effect of cognitive behavioral group treatment program on hypoactive sexual desire in women. Sex Rel Ther 2001; 16:145-164.
22. Bo K, Talseth T, Vinsnes A. Randomized controlled trial on the effect of pelvic floor muscle training on quality of life and sexual problems in genuine stress incontinent women. Acta Obstet Gynecol Scand 2000; 79:598-603.
23. Beji NK, Yalcin O, Erkan HA. The effect of pelvic floor training on sexual function of treated patients. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14:234-238.
24. Billups KL, Berman L, Berman J, et al. A new nonpharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001; 27:435-441.
25. Wilson SK, Delk JR, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001; 4:54-58.
26. Rioux JE, Devlin MC, Gelfand MM, et al. 17 beta-estradiol vaginal tablets versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7:156-161.
27. Davis S, Tran J. Testosterone influences libido and well being in women. Trend Endocrinol Metab 2001; 12:33-37.
28. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2002; 55:812-815.
29. Berman JR, Berman LA, Toler SM, et al., The Sildenafil Study Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo-controlled study. J Urol 2003; 170:2333-2338.
30. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003; 110:1014-1024.
31. Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171:1189-1193.
32. Kuensch E, Reiners K, Müller-Mattheis V, et al. Neurological risk profile in organic erectile dysfunction. J Neurol Neurosurg Psychiatry 1992; 55:275-281.
33. Rosen RC, Phillips NA, Gendrano NC, Ferguson DM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999; 25:137-144.
34. Rubio-Aurioles E, Lopez M, Lipezker M, et al. Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: a psychophysiological study. J Sex Marital Ther 2002; 28 (Suppl 1):205-215.
35. Rampin O. Mode of action of a new oral treatment for erectile dysfunction: apomoprhine SL. BJU Int 2001; 88 (Suppl 3):22-24.
36. Caruso S, Agnello C, Intelisano G, et al. Placebo-controlled study on the efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004; 63:955-959.
37. Bechara A, Bertolino MV, Casabe A, Fredotovich N. A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J Sex Med 2004; 1:209-214.
38. Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A 2004; 101:10201-10204.
39. Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3:628-638.
40. Hedlund P. PT-141 Palatin. Curr Opin Investig Drugs 2004; 5:456-462.
41. Walsh KE, Berman JR. Sexual dysfunction in the older woman: an overview of the current understanding and management. Drugs Aging 2004; 21:655-675.